AVMAPKI (avutometinib potassium)
ANTINEOPLASTIC - MEK1 AND MEK2 KINASE INHIBITORS·LOW-GRADE SEROUS OVARIAN CANCER WITH KRAS MUTATION
VERASTEM, INC.
Indication
Low-grade serous ovarian cancer with KRAS mutation
Low-grade serous ovarian cancer with KRAS mutation is a distinct, biomarker-defined subtype of epithelial ovarian carcinoma affecting the female reproductive system and peritoneal cavity. Read more about Low-grade serous ovarian cancer with KRAS mutation
3 drugs 1 manufacturers
Drugs that treat it
Common Low-grade serous ovarian cancer with KRAS mutation therapies.
AVMAPKI-FAKZYNJA (avutometinib potassium/defactinib hydrochloride)
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·LOW-GRADE SEROUS OVARIAN CANCER WITH KRAS MUTATION
VERASTEM, INC.
FAKZYNJA (defactinib hydrochloride)
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·LOW-GRADE SEROUS OVARIAN CANCER WITH KRAS MUTATION
VERASTEM, INC.
Filter & compare in the drug finder →Opens the drug finder with Low-grade serous ovarian cancer with KRAS mutation preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonLow-grade serous ovarian cancer with KRAS mutation is a distinct, biomarker-defined subtype of epithelial ovarian carcinoma affecting the female reproductive system and peritoneal cavity.
It typically arises de novo or from serous borderline precursors in younger adult females and is characterized histologically by uniform cell morphology, low mitotic activity, wild-type TP53, and frequent primary resistance to standard cytotoxic chemotherapy.
Pathophysiologically, the presence of an oncogenic KRAS mutation leads to constitutive, hyperactive signaling along the mitogen-activated protein kinase (MAPK/ERK) cascade, which drives sustained cellular proliferation and provides a targetable mechanism for MAPK-directed pathway inhibition.
- nih.gov
Low-grade serous ovarian cancer with KRAS mutation is a distinct, biomarker-defined subtype of epithelial ovarian carcinoma affecting the female reproductive system and peritoneal cavity It typically arises de novo or from serous borderline precursors in younger adult females and is characterized histologically by uniform cell morphology, low mitotic activity, wild-type TP53, and frequent primary resistance to standard cytotoxic chemotherapy Pathophysiologically, the presence of an oncogenic KRA...
- mypathologyreport.ca
Low-grade serous ovarian cancer with KRAS mutation is a distinct, biomarker-defined subtype of epithelial ovarian carcinoma affecting the female reproductive system and peritoneal cavity It typically arises de novo or from serous borderline precursors in younger adult females and is characterized histologically by uniform cell morphology, low mitotic activity, wild-type TP53, and frequent primary resistance to standard cytotoxic chemotherapy
- mdpi.com
Low-grade serous ovarian cancer with KRAS mutation is a distinct, biomarker-defined subtype of epithelial ovarian carcinoma affecting the female reproductive system and peritoneal cavity It typically arises de novo or from serous borderline precursors in younger adult females and is characterized histologically by uniform cell morphology, low mitotic activity, wild-type TP53, and frequent primary resistance to standard cytotoxic chemotherapy
- nih.gov
Pathophysiologically, the presence of an oncogenic KRAS mutation leads to constitutive, hyperactive signaling along the mitogen-activated protein kinase (MAPK/ERK) cascade, which drives sustained cellular proliferation and provides a targetable mechanism for MAPK-directed pathway inhibition
- stonybrookmedicine.edu
Pathophysiologically, the presence of an oncogenic KRAS mutation leads to constitutive, hyperactive signaling along the mitogen-activated protein kinase (MAPK/ERK) cascade, which drives sustained cellular proliferation and provides a targetable mechanism for MAPK-directed pathway inhibition
Personalize your experience
Follow Low-grade serous ovarian cancer with KRAS mutation and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.